Nektar Therapeutics (FRA:ITH) Inventories, Finished Goods : €3.99 Mil (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Inventories, Finished Goods?

Nektar Therapeutics's quarterly finished goods increased from Sep. 2023 (€0.86 Mil) to Dec. 2023 (€1.25 Mil) and increased from Dec. 2023 (€1.25 Mil) to Mar. 2024 (€3.99 Mil).

Nektar Therapeutics's annual finished goods increased from Dec. 2021 (€2.91 Mil) to Dec. 2022 (€5.55 Mil) but then declined from Dec. 2022 (€5.55 Mil) to Dec. 2023 (€1.25 Mil).

Nektar Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Nektar Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Inventories, Finished Goods Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

2.45

1.78

2.91

5.55

1.25

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															4.52	5.32	0.86	1.25	3.99

Nektar Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Nektar Therapeutics (FRA:ITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

NKTR:USA

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines